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Christianson syndrome (CS) is an X-linked neurodevelopmental disorder caused by deleterious mutations in SLC9A6.
Affected families organized the inaugural Christianson Syndrome Association conference to advance CS knowledge
and develop questions that may be prioritized in future research.
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Christianson syndrome (CS) is a novel, X-linked devel-
opmental brain disorder, clinically recognized by the
symptoms of global developmental delay, intellectual
disability, ataxia, epilepsy, non- or minimally verbal status,
ophthalmoplegia and most often postnatal microcephaly
[1]. CS is caused by deleterious mutations in SLC9A6,
an X-linked gene that codes for the endosomal Na+/H+
exchanger 6 (NHE6), which is believed to be involved
with circuit development [2,3]. Another report has also
demonstrated downregulation of SLC9A6 expression in
the autism postmortem brain [4], indicating that the
pathophysiology may be related to a subset of autism.
CS may be among the most common X-linked devel-
opmental brain disorders. In a large-scale sequencing
project in approximately 200 pedigrees with suspected
X-linked intellectual disability, two protein-truncating
mutations in SLC9A6 were found [5]. These data place
SLC9A6 among the top six genes with recurrent protein-
truncating mutations, and suggest that CS may consti-
tute approximately 1% to 2% of X-linked developmental
brain disorders. Assuming between 1% and 3% of the
world’s population is diagnosed with an intellectual dis-
ability, and approximately 10% to 20% of the causes are
due to X-linked genes, CS may affect between one in* Correspondence: eric_morrow@brown.edu
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unless otherwise stated.16,000 and one in 100,000 people. By comparison, this
represents 10% to 50% of the prevalence of Fragile-X
syndrome, the most common inherited form of intellec-
tual disability.
Organization of the meeting
The following is a meeting report of the Christianson
Syndrome Association (CSA) Inaugural Conference that
took place between June 27th and June 29th, 2013 at
the Warren Alpert Medical School of Brown University,
Providence, RI, USA. The event was organized by the
CSA board members, and was hosted by Dr Eric Morrow
of Brown University. Ten families traveled from across the
USA, Canada, and Europe to participate, and included
boys with CS, their parents, and their unaffected siblings.
CSA was founded in 2011 to impart a sustained vision of
hope for the future of patients with CS and their families
through advancing awareness and treatment. The con-
ference slogan, ‘A New Day Has Come’, reflects the con-
fidence that increasing awareness will bring exciting
new research and treatment [6].
Christianson Syndrome Association inaugural conference
The CSA symposium began on the evening of Thursday
27 June, as families were welcomed by board members
and invited to a ‘meet and greet’ event. This was an
exciting experience because most of the families had
never encountered another individual affected by CS
and because the boys were able to meet each other.
On Friday 28 June, the first full day began with a
welcome from Deborah Nash, president of CSA. Nash
reviewed the history and mission of CSA and introducedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Table 1 This table outlines the major research questions
that were designed in a collaborative discussion between
the executive board of the Christianson Syndrome
Association and parents of patients with Christianson
Syndrome
Priority questions proposed by Christianson
Syndrome families for research inquiry
1. What are optimal treatments for co-occurring epilepsy
with Christianson Syndrome?
2. To what extent is Christianson Syndrome progressive?
What is the predicted life expectancy for boys currently
affected with Christianson Syndrome?
3. What are the less-known symptoms in Christianson
Syndrome, and why are they present in the boys?
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helplessness when her child was diagnosed with CS, as no
pre-existing information had been available to help her.
Motivated by the early experiences with her son, she
founded the CSA in 2011. Nash concluded with the CSA
mission: ‘to advance the awareness and treatment of CS
through education and information, research, advocacy,
and support for individuals with CS, their families, and
other concerned parties’.
Friday’s main speaker was Dr Eric Morrow (Brown
University, USA) who presented his laboratory’s research
on CS (all of which was unpublished) and conducted a
question and answer session with the families. Many of
the families who had participated in Morrow’s research
were eager to discuss the early results. Morrow de-
scribed three types of research studies in his laboratory
with regard to CS. The first study is an analysis of the
clinical symptoms and developmental trajectories of
boys affected by CS. The goal of this ongoing study is to
teach families what to expect when their son is first
diagnosed and to guide future treatments of CS. Morrow
presented results from a soon-to-be-published study on
15 prospectively recruited families, with affected patients
ranging in age from 2 to 22 years. Among the important
new findings was the high rate of regressions seen in
over 40% of patients, ranging in age of regression from
15 months to 16 years (unpublished data). The second
study aims to develop mouse models for understanding
CS pathophysiology. Morrow discussed these current
projects on mice with SLC9A6 mutations, including a
study that demonstrates increased endosome acidity in
mutant neurons [3]. Morrow also reviewed a previously
published mouse study wherein histopathology consist-
ent with endo-lysosomal disease was seen in the hippo-
campus, cortex, amygdala, and cerebellum [7]. Morrow
reviewed a final study from his own laboratory, which
examines induced pluripotent stem cells from patients
with CS. The objective of this work is to investigate the
neurogenetic underpinnings of CS in human neuronal
cells, and to develop a patient-derived cellular system for
drug screening. Throughout his talk, Morrow empha-
sized the motto ‘research equals hope’ for CS patients
and their families.
For Friday’s second and third sessions, the families
were divided into two groups. Each group alternated
between hearing from Nicole Ener (Magnolia West High
School, USA), a teacher with considerable experience
working with CS, and taking a tour of the research facil-
ities in Morrow’s laboratory. The boys affected by CS
played together in an adjacent room with CSA-provided
care-takers and their unaffected siblings during these
sessions.
Ener has taught special education in the school system
and has specifically worked with a CS patient for severalyears. She guided a discussion of home and school inter-
ventions that would benefit children with CS. She also
provided principal suggestions for integrating children
with CS into a lesson plan. To ensure children with CS
maintain focus, she stressed the importance of mini-
mizing distractions. In order to optimize lessons, short
intense instruction is required, followed by a quick break.
Educators are encouraged to rotate often when working
with a child affected by CS because this approach to
teaching can be tiring. Additionally, people with CS
tend to engage in a high degree of oral stimulation so
this needs to be utilized, instead of challenged, when
planning lessons. Finally, boys with CS must stay phys-
ically active and should be encouraged to use their
motor skills as often as possible. Ener concluded by
suggesting that raising a child with CS takes a whole
team, and that parents need to be vigilant about com-
munication with all staff involved, especially teachers
and therapists.
In Friday’s final session, Morrow led a discussion to
determine the greatest problems each family encoun-
tered, and to agree on the lead research questions. In a
collaborative dialogue, families in attendance concurred
on a number of first-line questions (Table 1). The first
major question presented by the families was: What are
optimal treatments for co-occurring epilepsy that affects
all CS patients? The families voiced a possibility of
conducting treatment trials to determine efficacious anti-
epileptic therapies in CS. The second question was: What
is the predicted life expectancy for boys currently affected
with CS, and what is their anticipated quality of life as they
mature during puberty and into adulthood? The parents
were concerned with the undetermined clinical features of
CS beyond the school-age years. In Christianson’s first
report, from an analysis of a single large pedigree with CS
in South Africa, the article introduced the possibility that
there may be a risk of early mortality in CS [1]. Subse-
quent studies have also raised the possibility of a neurode-
generative component in CS [8]. The parents were eager
to meet more families with older CS patients, as the oldest
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The final question posed by families concerned the symp-
toms of CS that are not as commonly reported. The focus
was to understand why these symptoms were present in
their children and to elucidate other observed symptoms
that may be related to CS.
The event concluded on Saturday 29 June with a ses-
sion for parents and siblings, where the future goals of
CSA were discussed. This session included several con-
siderations for the CSA’s expansion. The parents estab-
lished that maintaining a network of support for CS
patients and their families was a crucial pillar of the
organization, and suggested further events for fundrais-
ing and awareness. The second goal was presented by
the executive board, and determined that continued
financial contribution for CS research should be a major
objective. Further, Morrow agreed to design a day-long
scientific meeting at the next CSA meeting with the
larger community of clinicians and researchers with an
interest in CS and/or relevant expertise regarding the
critical problems presented by CS. Researchers and
clinicians with interest in participating are encouraged
to contact Dr. Morrow to communicate their ideas and
interest (eric_morrow@brown.edu). The final goal aims to
expand the CSA, particularly in international locations
throughout Canada and Europe, in the hope of attract-
ing more families to the organization’s collaborative
benefits.
Conclusion
This inaugural conference was a major step made to unite
boys, families, care-givers, CSA staff, and researchers who
work for CS. At the meeting’s close, the attendees envi-
sioned a future of confidence and solidarity for CSA, as
their parting words were shared: ‘We came as strangers,
and left as a family’.
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